That's a good question Seel, I believe if K was mentioned in PFE's agent, this would have yielded a result on the USPTO search I did. My guess is the agent in use for those studies has been around long enough that K was still in its infancy developmentally and at that point and time not worth mentioning. I'd have to look into it again, as I do not recall if the exact specific drug from Pfizer was ever called out in the announcement of these studies. 

You see some of these other recent patent mentions still refer to Kevetrin as a preclinical agent, so given how long and arduous a task it is to write a patent,  I think there has been a relatively small window of time for K to be 'significant' enough to be worth mentioning as an HDAC inhibitor that could play well with others. It is great we are being mentioned in patents for other drugs owned by giants like Amgen, but of course there's a verrry long way to go. Let's hope Dana Farber lets Leo give us a proper and truly "comprehensive" update on Kevetrin next week! Have a great weekend!